Press Releases

05-12 Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot AQ
05-12 Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update AQ
04-17 Bolt Biotherapeutics : BDC-4182 AACR Poster (BBI-4182-101 TiP AACR 2026 Final) PU
03-12 Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot AQ
03-12 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update AQ
02-24 Bolt Biotherapeutics to Participate in Upcoming March Conferences AQ
11-12 Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot AQ
11-12 Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update AQ
01/10/25 Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 AQ
14/08/25 Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot AQ
14/08/25 Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update AQ
12/05/25 Bolt Biotherapeutics : Presentation (2025-05-12-BOLT BDC-3042 Event) PU
12/05/25 Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot AQ
12/05/25 Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GL
08/05/25 Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates GL
08/05/25 Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates AQ
30/04/25 Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 GL
25/04/25 Bolt Biotherapeutics : PD-L1 AACR Poster (PDL1 AACR 2025 final print) PU
25/04/25 Bolt Biotherapeutics : BDC 3042 AACR Poster (BDC 3042 AACR 2025 Poster v23Apr2025 Print) PU
25/04/25 Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 GL
20/04/25 Bolt Biotherapeutics : CEACAM5 AACR Poster (CEACAM5 2025 AACR poster FINAL) PU
25/03/25 Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 GL
24/03/25 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update GL
24/03/25 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update AQ
25/02/25 Bolt Biotherapeutics to Participate in Upcoming March Conferences AQ
No results for this search